Difference between revisions of "He SZ, et al. Leuk. Lymphoma (2015) cited as Ref 556 in DOI: 10.1038/s41392-020-0110-5 (Q9819)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Published In Name String (P102): Leuk. Lymphoma, #quickstatements; #temporary_batch_1590006349955)
(‎Created claim: Page(s) (P105): 1406-1415, #quickstatements; #temporary_batch_1590074839150)
 
(2 intermediate revisions by the same user not shown)
Property / Volume
 +
56
Property / Volume: 56 / rank
 +
Normal rank
Property / title
 +
A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia (English)
Property / title: A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia (English) / rank
 +
Normal rank
Property / Page(s)
 +
1406-1415
Property / Page(s): 1406-1415 / rank
 +
Normal rank

Latest revision as of 15:45, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
He SZ, et al. Leuk. Lymphoma (2015) cited as Ref 556 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    He SZ
    0 references
    0 references
    2015
    0 references
    Leuk. Lymphoma
    0 references
    56
    0 references
    A phase 1 study of the safety pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed refractory or high-risk acute myeloid leukemia (English)
    0 references
    1406-1415
    0 references